Aptamer Group (APTA) Competitors GBX 0.36 0.00 (-0.83%) (As of 12/20/2024 11:42 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors APTA vs. SAR, AREC, OKYO, OPTI, OBI, AOR, RLM, NSCI, ONC, and BVXShould you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include Sareum (SAR), Arecor Therapeutics (AREC), OKYO Pharma (OKYO), OptiBiotix Health (OPTI), Ondine Biomedical (OBI), AorTech International (AOR), Realm Therapeutics (RLM), NetScientific (NSCI), Oncimmune (ONC), and BiVictriX Therapeutics (BVX). These companies are all part of the "biotechnology" industry. Aptamer Group vs. Sareum Arecor Therapeutics OKYO Pharma OptiBiotix Health Ondine Biomedical AorTech International Realm Therapeutics NetScientific Oncimmune BiVictriX Therapeutics Sareum (LON:SAR) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Is SAR or APTA more profitable? Aptamer Group's return on equity of -187.53% beat Sareum's return on equity.Company Net Margins Return on Equity Return on Assets SareumN/A -257.72% -113.80% Aptamer Group N/A -187.53%-44.96% Do institutionals & insiders hold more shares of SAR or APTA? 11.7% of Aptamer Group shares are held by institutional investors. 5.0% of Sareum shares are held by insiders. Comparatively, 13.2% of Aptamer Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, SAR or APTA? Sareum has a beta of -1.08, indicating that its stock price is 208% less volatile than the S&P 500. Comparatively, Aptamer Group has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Which has stronger earnings & valuation, SAR or APTA? Sareum has higher earnings, but lower revenue than Aptamer Group. Sareum is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSareum£47.20K607.17-£4.25M-£0.06-442.50Aptamer Group£1.03M6.65-£7.01M-£0.08-4.46 Does the media prefer SAR or APTA? In the previous week, Sareum's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score. Company Overall Sentiment Sareum Neutral Aptamer Group Neutral Does the MarketBeat Community prefer SAR or APTA? Sareum received 82 more outperform votes than Aptamer Group when rated by MarketBeat users. CompanyUnderperformOutperformSareumOutperform Votes8266.13% Underperform Votes4233.87% Aptamer GroupN/AN/A SummaryAptamer Group beats Sareum on 7 of the 11 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Aptamer Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APTA vs. The Competition Export to ExcelMetricAptamer GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.85M£167.43M£5.15B£1.96BDividend YieldN/A3.64%5.12%5.22%P/E Ratio-4.46115.5187.111,912.44Price / Sales6.6518,799.931,116.56405,331.92Price / CashN/A13.0143.2329.27Price / Book0.368.744.792.83Net Income-£7.01M-£20.89M£120.55M£157.88M7 Day Performance-6.54%-1.05%-1.92%-2.05%1 Month Performance5.00%175.84%13.67%22.42%1 Year Performance-69.12%135.68%28.47%30.92% Aptamer Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APTAAptamer GroupN/AGBX 0.36-0.8%N/A-69.6%£6.85M£1.03M-4.4637Gap UpSARSareumN/AGBX 26-3.7%N/A-51.7%£28.07M£47,204.00-450.003,211ARECArecor TherapeuticsN/AGBX 70-0.7%N/A-63.3%£26.43M£4.90M-250.0010Gap DownOKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007News CoverageGap DownOPTIOptiBiotix HealthN/AGBX 22.93+1.5%N/A-26.9%£22.46M£1.26M-753.331OBIOndine BiomedicalN/AGBX 7.75flatN/A-6.2%£21.49M£1.63M-258.33N/AGap DownAORAorTech InternationalN/AGBX 123.50-2.4%N/AN/A£19.99M£539,000.00-33.383RLMRealm TherapeuticsN/AGBX 11.50flatN/AN/A£13.41M£501,919.00-0.66N/ANSCINetScientificN/AGBX 53.50flatN/AN/A£12.81M£1.45M-486.3626ONCOncimmuneN/AGBX 14.80-6.6%N/A-41.3%£10.97M£1.21M-528.3352Gap DownBVXBiVictriX TherapeuticsN/AGBX 10+17.6%N/AN/A£8.25MN/A-250.0017Gap UpHigh Trading Volume Related Companies and Tools Related Companies Sareum Alternatives Arecor Therapeutics Alternatives OKYO Pharma Alternatives OptiBiotix Health Alternatives Ondine Biomedical Alternatives AorTech International Alternatives Realm Therapeutics Alternatives NetScientific Alternatives Oncimmune Alternatives BiVictriX Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:APTA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredThis Warning flashed just before the dot-com bust and the Great DepressionA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptamer Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptamer Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APTA Stock Alerts